Expression and function of transforming growth factor‑β‑activated protein kinase 1 in gastric cancer

Yang,Yue; Qiu,Yudong; Tang,Mubai; Wu,Zhaoshu; Hu,Weidong; Chen,Chaobo

doi:10.3892/mmr.2017.6998

Expression and function of transforming growth factor‑β‑activated protein kinase 1 in gastric cancer

Authors:
- Yue Yang
- Yudong Qiu
- Mubai Tang
- Zhaoshu Wu
- Weidong Hu
- Chaobo Chen
View Affiliations

Affiliations: Department of Surgery, The Third Affiliated Hospital, Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu 210001, P.R. China, Department of Hepatopancreatobiliary Surgery, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210000, P.R. China, Department of General Surgery, Wuxi Xishan People's Hospital, Wuxi, Jiangsu 214011, P.R. China
Published online on: July 15, 2017 https://doi.org/10.3892/mmr.2017.6998
Pages: 3103-3110
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression and role of transforming growth factor (TGF) ‑β‑activated protein kinase 1 (TAK1) in human gastric cancer. Immunohistochemistry was performed to investigate the expression of TAK1 in surgical specimens of human gastric cancer tissue and adjacent normal tissue. The association between TAK1 and clinicopathologic factors was analyzed and the association between TAK1 expression and the overall survival rates was evaluated using Kaplan‑Meier curves. In addition, the effect of the TAK1 selective inhibitor 5Z‑7‑oxozeaenol (OZ) on the biological characteristics of MGC803 human gastric cancer cells in vitro were investigated. The role of TAK1 in gastric cancer cell proliferation, apoptosis and invasion were determined by cell proliferation assays, flow cytometry analysis and transwell invasion assays, respectively. The findings of the present study demonstrated that the positive expression rate of TAK1 in gastric cancer and adjacent normal tissues was 70.5 and 25.9%, respectively. Furthermore, TAK1 expression was significantly associated with advanced N stage and pathological stage (P<0.05). Survival analysis of 139 patients with gastric cancer indicated a lower overall survival rate of patients in the TAK1‑positive group compared with the TAK1‑negative group (P<0.05). In addition, treatment with the TAK1 selective inhibitor OZ reduced the proliferation and invasion abilities of MGC803 cells and significantly reduced the expression levels of phosphorylated‑TAK1 (Thr187), nuclear p65, cyclin D1, Bcl‑2 apoptosis regulator and matrix metallopeptidase (MMP)9 (P<0.05). OZ treatment significantly increased the expression levels of cytosolic cytochrome c and cleaved caspase 3 and the apoptosis rate in MGC803 cells (P<0.05). In conclusion, these findings suggest that increased TAK1 expression may be involved in the progression of gastric cancer; therefore, TAK1 may be used as a future therapeutic target for gastric cancer treatment.

View Figures

View References

1	Digklia A and Wagner AD: Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol. 22:2403–2414. 2016. View Article : Google Scholar : PubMed/NCBI
2	Lordick F and Janjigian YY: Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol. 13:348–360. 2016. View Article : Google Scholar : PubMed/NCBI
3	Tomasello G, Ghidini M, Liguigli W, Ratti M, Toppo L and Passalacqua R: Targeted therapies in gastric cancer treatment: Where we are and where we are going. Invest New Drugs. 34:378–393. 2016. View Article : Google Scholar : PubMed/NCBI
4	Karimi P, Islami F, Anandasabapathy S, Freedman ND and Kamangar F: Gastric cancer: Descriptive epidemiology, risk factors, screening and prevention. Cancer Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI
5	Liu X and Meltzer SJ: Gastric cancer in the era of precision medicine. Cell Mol Gastroenterol Hepatol. 3:348–358. 2017. View Article : Google Scholar : PubMed/NCBI
6	Lee SY and Oh SC: Changing strategies for target therapy in gastric cancer. World J Gastroenterol. 22:1179–1189. 2016. View Article : Google Scholar : PubMed/NCBI
7	Sakurai H: Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci. 33:522–530. 2012. View Article : Google Scholar : PubMed/NCBI
8	Huang HL, Chiang CH, Hung WC and Hou MF: Targeting of TGF-β-activated protein kinase 1 inhibits chemokine (C-C motif) receptor 7 expression, tumor growth and metastasis in breast cancer. Oncotarget. 6:995–1007. 2015. View Article : Google Scholar : PubMed/NCBI
9	Lin P, Niu W, Peng C, Zhang Z and Niu J: The role of TAK1 expression in thyroid cancer. Int J Clin Exp Pathol. 8:14449–14456. 2015.PubMed/NCBI
10	Wu M, Shi L, Cimic A, Romero L, Sui G, Lees CJ, Cline JM, Seals DF, Sirintrapun JS, McCoy TP, et al: Suppression of Tak1 promotes prostate tumorigenesis. Cancer Res. 72:2833–2843. 2012. View Article : Google Scholar : PubMed/NCBI
11	Bosman MC, Schepers H, Jaques J, Brouwers-Vos AZ, Quax WJ, Schuringa JJ and Vellenga E: The TAK1-NF-κB axis as therapeutic target for AML. Blood. 124:3130–3140. 2014. View Article : Google Scholar : PubMed/NCBI
12	Kilty I and Jones LH: TAK1 selective inhibition: State of the art and future opportunities. Future Med Chem. 7:23–33. 2015. View Article : Google Scholar : PubMed/NCBI
13	Wu J, Powell F, Larsen NA, Lai Z, Byth KF, Read J, Gu RF, Roth M, Toader D, Saeh JC and Chen H: Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol. ACS Chem Biol. 8:643–650. 2013. View Article : Google Scholar : PubMed/NCBI
14	Fakhouri L, El-Elimat T, Hurst DP, Reggio PH, Pearce CJ, Oberlies NH and Croatt MP: Isolation, semisynthesis, covalent docking and transforming growth factor beta-activated kinase 1 (TAK1)-inhibitory activities of (5Z)-7-oxozeaenol analogues. Bioorg Med Chem. 23:6993–6999. 2015. View Article : Google Scholar : PubMed/NCBI
15	Arici DS, Tuncer E, Ozer H, Simek G and Koyuncu A: Expression of retinoblastoma and cyclin D1 in gastric carcinoma. Neoplasma. 56:63–67. 2009. View Article : Google Scholar : PubMed/NCBI
16	Seo JH, Jeong ES and Choi YK: Therapeutic effects of lentivirus-mediated shRNA targeting of cyclin D1 in human gastric cancer. BMC Cancer. 14:1752014. View Article : Google Scholar : PubMed/NCBI
17	Akter H, Park M, Kwon OS, Song EJ, Park WS and Kang MJ: Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer. Tumour Biol. 36:6053–6062. 2015. View Article : Google Scholar : PubMed/NCBI
18	Zhu J, Li Q, He JT and Liu GY: Expression of TAK1/TAB1 expression in non-small cell lung carcinoma and adjacent normal tissues and their clinical significance. Int J Clin Exp Pathol. 8:15801–15807. 2015.PubMed/NCBI
19	Yang M and Huang CZ: Mitogen-activated protein kinase signaling pathway and invasion and metastasis of gastric cancer. World J Gastroenterol. 21:11673–11679. 2015. View Article : Google Scholar : PubMed/NCBI
20	Li X, Tu J, Zhang D, Xu Z, Yang G, Gong L and Yu M: The clinical significance of HER-2 and NF-KB expression in gastric cancer. Hepatogastroenterology. 60:1519–1523. 2013.PubMed/NCBI
21	Li Q, Yu YY, Zhu ZG, Ji YB, Zhang Y, Liu BY, Chen XH and Lin YZ: Effect of NF-kappaB constitutive activation on proliferation and apoptosis of gastric cancer cell lines. Eur Surg Res. 37:105–110. 2005. View Article : Google Scholar : PubMed/NCBI
22	Uetsuka H, Haisa M, Kimura M, Gunduz M, Kaneda Y, Ohkawa T, Takaoka M, Murata T, Nobuhisa T, Yamatsuji T, et al: Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res. 289:27–35. 2003. View Article : Google Scholar : PubMed/NCBI
23	Pak KH, Kim DH, Kim H, Lee DH and Cheong JH: Differences in TGF-b1 signaling and clinicopathologic characteristics of histologic subtypes of gastric cancer. BMC Cancer. 16:602015. View Article : Google Scholar
24	Zhang J, Li B, Wu H, Ou J, Wei R, Liu J, Cai W, Liu X, Zhao S, Yang J, et al: Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi. Tumour Biol. 37:531–539. 2016. View Article : Google Scholar : PubMed/NCBI
25	Hrabe JE, O'Leary BR, Fath MA, Rodman SN, Button AM, Domann FE, Spitz DR and Mezhir JJ: Disruption of thioredoxin metabolism enhances the toxicity of transforming growth factor β-activated kinase 1 (TAK1) inhibition in KRAS-mutated colon cancer cells. Redox Biol. 5:319–327. 2015. View Article : Google Scholar : PubMed/NCBI
26	Cai PC, Shi L, Liu VW, Tang HW, Liu IJ, Leung TH, Chan KK, Yam JW, Yao KM, Ngan HY and Chan DW: Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling. Oncotarget. 5:7549–7562. 2014. View Article : Google Scholar : PubMed/NCBI
27	Fan Y, Cheng J, Vasudevan SA, Patel RH, Liang L, Xu X, Zhao Y, Jia W, Lu F, Zhang H, et al: TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy. Apoptosis. 18:1224–1234. 2013. View Article : Google Scholar : PubMed/NCBI
28	Singhirunnusorn P, Suzuki S, Kawasaki N, Saiki I and Sakurai H: Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-beta-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J Biol Chem. 280:7359–7368. 2005. View Article : Google Scholar : PubMed/NCBI
29	Choo MK, Kawasaki N, Singhirunnusorn P, Koizumi K, Sato S, Akira S, Saiki I and Sakurai H: Blockade of transforming growth factor-beta-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade. Mol Cancer Ther. 5:2970–2976. 2006. View Article : Google Scholar : PubMed/NCBI
30	Cao H, Lu J, Du J, Xia F, Wei S, Liu X, Liu T, Liu Y and Xiang M: TAK1 inhibition prevents the development of autoimmune diabetes in NOD mice. Sci Rep. 5:145932015. View Article : Google Scholar : PubMed/NCBI
31	Song Z, Zhu X, Jin R, Wang C, Yan J, Zheng Q, Nanda A, Granger DN and Li G: Roles of the kinase TAK1 in CD40-mediated effects on vascular oxidative stress and neointima formation after vascular injury. PloS One. 9:e1016712014. View Article : Google Scholar : PubMed/NCBI
32	Guo JQ, Li SJ and Guo GX: Long noncoding RNA AFAP1-AS1 promotes cell proliferation and apoptosis of gastric cancer cells via PTEN/p-AKT pathway. Dig Dis Sci. Apr 27–2017.(Epub ahead of print). View Article : Google Scholar
33	Tong K, Xin C and Chen W: Isoimperatorin induces apoptosis of the SGC-7901 human gastric cancer cell line via the mitochondria-mediated pathway. Oncol Lett. 13:518–524. 2017.PubMed/NCBI
34	Wang D, Li Y, Cui P, Zhao Q, Tan BB, Zhang ZD, Liu Y and Jia N: Zerumbone induces gastric cancer cells apoptosis: Involving cyclophilin A. Biomed Pharmacother. 83:740–745. 2016. View Article : Google Scholar : PubMed/NCBI
35	Shen X, Si Y, Wang Z, Wang J, Guo Y and Zhang X: Quercetin inhibits the growth of human gastric cancer stem cells by inducing mitochondrial-dependent apoptosis through the inhibition of PI3K/Akt signaling. Int J Mol Med. 38:619–626. 2016.PubMed/NCBI
36	Yang LQ, Fang DC, Wang RQ and Yang SM: Effect of NF-kappaB, survivin, Bcl-2 and Caspase3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. World J Gastroenterol. 10:22–25. 2004.PubMed/NCBI
37	Chang MS, Lee HS, Jung EJ, Kim CW, Lee BL and Kim WH: Cell-cycle regulators, bcl-2 and NF-kappaB in Epstein-Barr virus-positive gastric carcinomas. Int J Oncol. 27:1265–1272. 2005.PubMed/NCBI
38	Dolcet X, Llobet D, Pallares J and Matias-Guiu X: NF-kB in development and progression of human cancer. Virchows Arch. 446:475–482. 2005. View Article : Google Scholar : PubMed/NCBI
39	Buglio D, Palakurthi S, Byth K, Vega F, Toader D, Saeh J, Neelapu SS and Younes A: Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood. 120:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
40	Park BB, Yoon Js, Kim Es, Choi J, Won Yw, Choi Jh and Lee YY: Inhibitory effects of eupatilin on tumor invasion of human gastric cancer MKN-1 cells. Tumour Biol. 34:875–885. 2013. View Article : Google Scholar : PubMed/NCBI
41	Zhang QW, Liu L, Chen R, Wei YQ, Li P, Shi HS and Zhao YW: Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: A meta-analysis. Asian Pac J Cancer Prev. 13:2903–2908. 2012. View Article : Google Scholar : PubMed/NCBI
42	Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C and Strauss M: NF-kappaB function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 19:2690–2698. 1999. View Article : Google Scholar : PubMed/NCBI
43	Lam CR, Tan C, Teo Z, Tay CY, Phua T, Wu YL, Cai PQ, Tan LP, Chen X, Zhu P and Tan NS: Loss of TAK1 increases cell traction force in a ROS-dependent manner to drive epithelial-mesenchymal transition of cancer cells. Cell Death Dis. 4:e8482013. View Article : Google Scholar : PubMed/NCBI
44	Omori E, Matsumoto K, Zhu S, Smart RC and Ninomiya-Tsuji J: Ablation of TAK1 upregulates reactive oxygen species and selectively kills tumor cells. Cancer Res. 70:8417–8425. 2010. View Article : Google Scholar : PubMed/NCBI